The latest report from Fore Pharma, Idiopathic Pulmonary Fibrosis Pipeline Highlights – 2017 Update, provides most up-to-date information on key pipeline products in the global Idiopathic Pulmonary Fibrosis market. It covers emerging therapies for Idiopathic Pulmonary Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages: The report provides Idiopathic Pulmonary Fibrosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes: The report provides Idiopathic Pulmonary Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company: The report provides Idiopathic Pulmonary Fibrosis pipeline products by the company.
Short-term Launch Highlights: Find out which Idiopathic Pulmonary Fibrosis pipeline products will be launched in the US and Ex-US till 2020.